Myeloproliferative neoplasms-unclassifiable (MPN-U): A carefully curated series of 30 Mayo Clinic patients

Abstract Background Although myeloproliferative neoplasm-unclassifiable (MPN-U) stands as a distinct entity in the International Consensus Classification (ICC) for myeloproliferative neoplasms, its diagnosis and management remain challenging due to the overlapping clinico-pathological characteristics with other MPNs. In the current study, we describe a well-defined cohort of patients with MPN-U and compare their presentation and outcome with those of a separate cohort with essential thrombocythemia (ET). Methods Diagnostic criteria were according to the ICC (Blood 2022; 140:1200). Non-driver mutations were screened by next-generation sequencing (NGS) and were available for subsets of patients with MPN-U or ET. Conventional statistical methods were employed, using JMP Pro 18.0.0 software SAS Institute, Cary, NC, USA. Results Thirty Mayo Clinic patients who met the ICC criteria for MPN-U (median age 64 years; range 33-94; 60% males) and 658 with ET (median age 60 years; range 18-90; 36% males) were included in the current study. Table 1 outlines a comparative list of presenting characteristics (including mutations), clinical outcomes, and treatment details between patients with MPN-U vs. ET. JAK2 mutations were significantly more prevalent in MPN-U cohort (87% vs. 63% in ET; p<0.01) and CALR mutations less common (3% vs. 25%; p<0.01). Other somatic mutations, including ASXL1, SRSF2, and EZH2 were more frequently observed in the MPN-U group (p<0.05 in all). Abnormal karyotype was reported in 14% of patients with MPN-U vs. 8% with ET (p=0.3). Compared to patients with ET, those with MPN-U were more likely to be males (60% vs. 36%; p<0.01) and, as expected from disease presentation and indications for diagnostic work up of suspected cases, present with venous thrombosis (43% vs. 10%; p<0.01) and palpable splenomegaly (40% vs. 8.5%; p<0.01). Similarly, they were less likely to display thrombocytosis or leukocytosis (p<0.01 for both). Portal, superior mesenteric, and hepatic vein thromboses constituted 77% (vs. 27% in ET; p<0.01) of the venous events in MPN-U; in contrast, the incidences of pre-diagnosis arterial events were similar between the two groups (10% vs. 12%; p=0.7). At a median follow-up of 2.8 years in the MPN-U cohort, 6 (20%) deaths and 1 (3%) leukemic transformation were documented while 3 (10%) patients progressed to meet the diagnostic criteria for polycythemia vera. Four (13%) patients with MPN-U experienced venous thrombo-embolic events (VTEs) including 2 with recurrent VTEs, despite active therapy with systemic anticoagulation and aspirin. The ET cohort was followed for a median of 7.3 years with 161 (24%) deaths, 23 (3%) leukemic transformations, and 66 (10%) VTEs. Among the latter, 27 (41%) had recurrent episodes despite treatment with systemic anticoagulation, aspirin, and/or cytoreductive drugs. Notably, patients with MPN-U were less likely to receive aspirin and cytoreductive therapy during the clinical course (77% vs. 91% and 37% vs. 79%; p<0.01 for both, respectively). Long-term survival rates were similar between MPN-U and ET (15-year survival 70% vs. 65%; p=0.1). Consistent with previous associations seen in ET, patients with JAK2-mutated MPN-U were more likely to be males (58% vs. 30%; p<0.01, Table 2), and display a lower platelet and leukocyte count at the time of diagnosis (p<0.01 for both). These patients were also more likely to present with venous thrombosis (50% vs. 12% in JAK2 wild-type cases; p<0.01) and palpable splenomegaly (46% vs. 9%; p<0.01). Of note, the incidences of pre- and post-diagnosis arterial and post-diagnosis venous events were similar between JAK2-mutated MPN-U vs. JAK2-mutated ET patients (12% vs. 14%; p=0.7, 4% vs. 12.5%; p=0.1, and 15% vs. 12%, p=0.6, respectively). Similarly, long-term outcomes including deaths (15% vs. 26%; p=0.2), leukemic transformations (4% vs. 4%; p=0.9), and 15-year survival rates (78% vs. 60%; p=0.9) were also comparable between the two groups. Conclusion The findings from the current study were not unexpected and underline the ongoing challenges that face formal classification systems in formulating accurate diagnostic criteria for patients with MPN-U whose clinical presentation is biased by disease definitions. Regardless, it is comforting to document a favorable long-term outcome that appeared to be similar to that of ET while venous thrombosis remains a treatment challenge in both groups.